Ractigen Therapeutics Achieves IND Approval for Innovative saRNA Treatment in Bladder Cancer Ractigen Therapeutics has received IND approval from China's NMPA for RAG-01, a promising saRNA treatment for non-muscle invasive bladder cancer, marking a crucial step in cancer therapy.

Ractigen Therapeutics Achieves IND Approval for Innovative saRNA Treatment in Bladder Cancer #China #Ractigen #RAG-01 #Nantong #saRNA

Ractigen Therapeutics Begins Groundbreaking Study of saRNA Treatment for Duchenne Muscular Dystrophy Ractigen Therapeutics announces the first patient has been dosed in a clinical trial for RAG-18, a novel saRNA treatment for Duchenne Muscular Dystrophy, offering new hope.

Ractigen Therapeutics Begins Groundbreaking Study of saRNA Treatment for Duchenne Muscular Dystrophy #China #Beijing #Duchenne #Ractigen #RAG-18

Ractigen Therapeutics Marks Major Milestone with First Patient Dosed in DMD RAG-18 Study Ractigen Therapeutics celebrates an important milestone as it successfully doses the first patient in a trial for RAG-18, targeting Duchenne Muscular Dystrophy, a significant step towards innovative treatments.

Ractigen Therapeutics Marks Major Milestone with First Patient Dosed in DMD RAG-18 Study #China #Beijing #Duchenne_Muscular_Dystrophy #Ractigen #RAG-18

Ractigen's RAG-01 Demonstrates Early Efficacy in Bladder Cancer Trial Presented at EAU 2025 Ractigen Therapeutics revealed promising results from its Phase I trial for RAG-01, a new treatment for non-muscle invasive bladder cancer, showcasing a 66.7% response rate.

Ractigen's RAG-01 Demonstrates Early Efficacy in Bladder Cancer Trial Presented at EAU 2025 #China #Bladder_Cancer #Ractigen #RAG-01 #Nantong